Skip to main content

Black Diamond Therapeutics, Inc.

BDTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001701541

No open-market purchases or sales by Black Diamond Therapeutics, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $64.9M in total; no superinvestor holds it.

13F holders, Q1 2021

Institutional positions in Black Diamond Therapeutics, Inc. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
113
No complete 13F data for Q4 2020
Shares held
29.1M
No complete 13F data for Q4 2020
Total value
$705.5M
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting BDTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 113 institutions
Q1 2021: 113 institutionsQ2 2021: 102 institutionsQ3 2021: 101 institutionsQ4 2021: 95 institutionsQ1 2022: 87 institutionsQ2 2022: 74 institutionsQ3 2022: 69 institutionsQ4 2022: 59 institutionsQ1 2023: 50 institutionsQ2 2023: 74 institutionsQ3 2023: 73 institutionsQ4 2023: 76 institutionsQ1 2024: 88 institutionsQ2 2024: 90 institutionsQ3 2024: 96 institutionsQ4 2024: 88 institutionsQ1 2025: 85 institutionsQ2 2025: 94 institutionsQ3 2025: 91 institutionsQ4 2025: 104 institutionsQ1 2026: 104 institutionsQ2 2026: 96 institutions
Value heldQ1 2021: $705.5M
Q1 2021: $705.5MQ2 2021: $309.6MQ3 2021: $206.3MQ4 2021: $123.7MQ1 2022: $63.5MQ2 2022: $52.9MQ3 2022: $36.3MQ4 2022: $37.9MQ1 2023: $40.6MQ2 2023: $209.2MQ3 2023: $106.8MQ4 2023: $107.1MQ1 2024: $199.9MQ2 2024: $217.9MQ3 2024: $211.9MQ4 2024: $102.5MQ1 2025: $63.0MQ2 2025: $95.8MQ3 2025: $147.0MQ4 2025: $92.0MQ1 2026: $82.0MQ2 2026: $64.9M
Institutions holding BDTX and their total value by quarter
QuarterHoldersValue
Q2 202696$64.9M
Q1 2026104$82.0M
Q4 2025104$92.0M
Q3 202591$147.0M
Q2 202594$95.8M
Q1 202585$63.0M
Q4 202488$102.5M
Q3 202496$211.9M
Q2 202490$217.9M
Q1 202488$199.9M
Q4 202376$107.1M
Q3 202373$106.8M
Q2 202374$209.2M
Q1 202350$40.6M
Q4 202259$37.9M
Q3 202269$36.3M
Q2 202274$52.9M
Q1 202287$63.5M
Q4 202195$123.7M
Q3 2021101$206.3M
Q2 2021102$309.6M
Q1 2021113$705.5M

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding Black Diamond Therapeutics, Inc..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding BDTX in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Wellington Management Group LLP596,546$14.5M0.00%––
Wells Fargo & Company669,854$16.3M0.00%––
Federated Hermes, Inc.875,952$21.3M0.04%––
Deerfield Management Company, L.P. (Series C)1,047,599$25.4M0.53%––
Artal Group S.A.1,646,517$39.9M0.85%––
State Street Corp1,794,638$43.5M0.00%––
Vanguard Group Inc1,875,985$45.5M0.00%––
BlackRock Inc.1,930,585$46.8M0.00%––
Boxer Capital, LLC2,014,858$48.9M1.66%––
FMR LLC2,091,288$50.7M0.00%––
Bellevue Group AG2,243,000$54.4M0.58%––
Ra Capital Management, L.P.2,589,904$62.8M0.95%––
NEA Management Company, LLC3,449,845$83.7M1.89%––